• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of Formulation on the Pharmacokinetic Profile of Dutasteride.

作者信息

Michel Martin C

机构信息

Department of Pharmacology, Johannes Gutenberg University, Obere Zahlbacher Str. 67, 55131, Mainz, Germany.

出版信息

Clin Drug Investig. 2016 Sep;36(9):769-770. doi: 10.1007/s40261-016-0429-4.

DOI:10.1007/s40261-016-0429-4
PMID:27364517
Abstract
摘要

相似文献

1
Impact of Formulation on the Pharmacokinetic Profile of Dutasteride.制剂对度他雄胺药代动力学特征的影响。
Clin Drug Investig. 2016 Sep;36(9):769-770. doi: 10.1007/s40261-016-0429-4.
2
Formulation and in vivo evaluation of a self-microemulsifying drug delivery system of dutasteride.度他雄胺自微乳化药物递送系统的制剂与体内评价
Drug Res (Stuttg). 2013 Apr;63(4):203-9. doi: 10.1055/s-0033-1334965. Epub 2013 Mar 13.
3
Preparation and in vivo evaluation of a dutasteride-loaded solid-supersaturatable self-microemulsifying drug delivery system.度他雄胺固体过饱和自微乳化药物递送系统的制备及体内评价
Int J Mol Sci. 2015 May 13;16(5):10821-33. doi: 10.3390/ijms160510821.
4
Design of a gelatin microparticle-containing self-microemulsifying formulation for enhanced oral bioavailability of dutasteride.含明胶微粒的自微乳化制剂设计用于提高度他雄胺的口服生物利用度
Drug Des Devel Ther. 2015 Jun 23;9:3231-8. doi: 10.2147/DDDT.S86458. eCollection 2015.
5
Enhanced oral bioavailability and controlled release of dutasteride by a novel dry elixir.一种新型干糖浆剂提高度他雄胺的口服生物利用度并实现控释
Biomed Mater Eng. 2014;24(1):571-9. doi: 10.3233/BME-130844.
6
Impurity profile study of dutasteride.
Pharmazie. 2007 Oct;62(10):743-6.
7
Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS.度他雄胺和非那雄胺治疗意大利男性下尿路症状的临床效果及经济影响。
Arch Ital Urol Androl. 2013 Dec 31;85(4):200-6. doi: 10.4081/aiua.2013.4.200.
8
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.双重5α-还原酶抑制剂度他雄胺可显著抑制良性前列腺增生男性体内的双氢睾酮。
J Clin Endocrinol Metab. 2004 May;89(5):2179-84. doi: 10.1210/jc.2003-030330.
9
Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.度他雄胺在男性雄激素性秃发患者毛发再生及毛囊小型化逆转方面优于非那雄胺：一项随机对照开放标签、评估者盲法研究。
Indian J Dermatol Venereol Leprol. 2017 Jan-Feb;83(1):47-54. doi: 10.4103/0378-6323.188652.
10
Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.度他雄胺可降低前列腺癌风险，从而改善良性前列腺增生的预后：度他雄胺减少前列腺癌事件（REDUCE）试验的二次分析。
Urology. 2011 Sep;78(3):641-6. doi: 10.1016/j.urology.2011.03.063. Epub 2011 Jul 20.

本文引用的文献

1
Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies.制剂对度他雄胺药代动力学的影响：两项I期研究的结果
Clin Drug Investig. 2016 Sep;36(9):763-767. doi: 10.1007/s40261-016-0419-6.
2
Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.度他雄胺与坦索罗辛固定剂量复方制剂（Duodart®）治疗初治的中度症状性良性前列腺增生男性患者的疗效和安全性，与症状未改善时开始坦索罗辛治疗并给予生活方式建议的观察等待策略相比：2年CONDUCT研究结果
BJU Int. 2015 Sep;116(3):450-9. doi: 10.1111/bju.13033. Epub 2015 Jan 29.
3
Pharmacokinetic bioequivalence studies of a fixed-dose combination of tamsulosin and dutasteride in healthy volunteers.坦索罗辛与度他雄胺固定剂量复方制剂在健康志愿者中的药代动力学生物等效性研究。
Clin Drug Investig. 2014 May;34(5):335-49. doi: 10.1007/s40261-014-0179-0.
4
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.EAU 指南：非神经原性男性下尿路症状（包括良性前列腺梗阻）的治疗和随访。
Eur Urol. 2013 Jul;64(1):118-40. doi: 10.1016/j.eururo.2013.03.004. Epub 2013 Mar 13.
5
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.度他雄胺和坦索罗辛联合治疗对有症状的良性前列腺增生症男性临床结局的影响：来自 CombAT 研究的 4 年结果。
Eur Urol. 2010 Jan;57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19.
6
Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations.格列本脲透皮贴剂：物理化学、药效学及药代动力学评价
J Pharm Sci. 2004 Jun;93(6):1577-94. doi: 10.1002/jps.20058.
7
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.多沙唑嗪、非那雄胺及联合治疗对良性前列腺增生临床进展的长期影响。
N Engl J Med. 2003 Dec 18;349(25):2387-98. doi: 10.1056/NEJMoa030656.
8
Dutasteride.度他雄胺
Drugs Aging. 2003;20(12):905-16; discussion 917-8. doi: 10.2165/00002512-200320120-00005.
9
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.多沙唑嗪与非那雄胺单独或联合使用治疗有症状的良性前列腺增生的疗效和耐受性：欧洲多沙唑嗪前瞻性联合治疗（PREDICT）试验
Urology. 2003 Jan;61(1):119-26. doi: 10.1016/s0090-4295(02)02114-3.
10
Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.
Eur Urol. 1998 Sep;34(3):169-75. doi: 10.1159/000019706.